Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience

Conclusions In limited resource countries like Egypt, we suggest that the use of sorafenib for the treatment of advanced HCC cases should be restricted to a highly selected subgroup of patients with good performance and child A.
Source: Journal of the Egyptian National Cancer Institute - Category: Cancer & Oncology Source Type: research